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1. Introduction 
DNA repair is essential to genomic integrity of the cell. Numerous studies have provided 
compelling evidence that hereditary defects in DNA repair are linked with predispositions 
to cancer, shedding light on the mechanism of DNA repair and its importance in cancer 
biology. The majority of human cancers however rarely undergo somatic mutations in DNA 
repair genes, yet they acquire genetic alterations as they progress. Little is known about the 
mechanism of genetic alteration during malignant progression. We and others have shown 
recently that hypoxia—oxygen deficiency—plays an important role in inhibiting DNA 
repair. Tumor hypoxia gives rise to the over-expression and activation of hypoxia-inducible 
factor 1α (HIF-1α), an oxygen-sensitive transcription factor commonly over-expressed in 
human cancers. Although HIF-1α is best known for its transcriptional up-regulation of a 
host of target genes responsible for tumor growth and survival, in this chapter we describe a 
novel mechanism by which HIF-1α inhibits DNA repair, thereby promoting genetic 
alterations and malignant progression.  
2. Tumor hypoxia and hypoxic response 
2.1 Role of hypoxia in tumor progression 
In mammals, molecular oxygen is required for aerobic metabolism to maintain intracellular 
bioenergetics and to serve as an electron acceptor. Although the oxygen concentration in 
ambient air is approximately 21%, oxygen levels in mammalian tissues are generally 
maintained at 2–9%. Tissues become hypoxic when oxygen levels drop below 2% and 
severely hypoxic or anoxic when they are less than 0.02% (Bertout et al, 2008). Whereas mild 
hypoxia is part of normal development and physiology, as well as pathophysiology, severe 
hypoxia occurs mostly in pathophysiological conditions. 
Human cancers frequently experience mild to severe hypoxia arising from rapid cell 
proliferation that outstrips oxygen supply and aberrant angiogenic processes that yield 
vascular anomaly, such as vessel tortuosity, arteriovenous shunts, and blind ends. 
Consequently, despite rampant angiogenic response, necrotic lesions become conspicuous 
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as a result of severe hypoxia or anoxia, especially in advanced human cancers 
accompanying cell proliferation. By contrast, benign tumors are less hypoxic, with cells 
proliferating at a pace compatible with vasculature development. Therefore, the degree of 
malignancy appears to be associated with the severity of hypoxia. 
Many studies have indicated that hypoxia promotes tumor metabolism, angiogenesis, and 
metastasis (Bertout et al, 2008; Giaccia et al, 2003; Harris, 2002; Semenza, 2003). Solid tumors 
manifest enhanced glucose consumption resulting from hypoxic switching to anaerobic 
glycolysis from the tricarboxylic acid cycle for bioenergetics. In advanced human gliomas, 
tumor angiogenesis is rampant and frequently accompanied by rapid cell proliferation. 
Hypoxia confers metastatic potential by altering extracellular matrix function and increasing 
the motility of tumor cells.  
Moreover, it has long been recognized that tumor hypoxia is tightly linked with DNA 
damage, mutation, and over-replication (Bindra & Glazer, 2005; Bristow & Hill, 2008; Huang 
et al, 2007). It is proposed that hypoxia provides a physiological selective pressure in tumors 
for the expansion of apoptosis-resistant variants by acquiring p53 mutations (Graeber et al, 
1996). Hypoxia also induces genomic rearrangement through activation of fragile sites, 
thereby triggering breakage–fusion–bridge cycles and, in turn, gene amplification (Coquelle 
et al, 1998). Furthermore, hypoxia is known to contribute to the development of resistance to 
radiation therapy and chemotherapy by, for example, up-regulating the expression of the 
multidrug resistance gene ABCB1, also known as MDR1.   
2.2 Hypoxic response 
Through evolution, mammals have developed a coordinated physiological system to cope 
with hypoxic stress (Bunn & Poyton, 1996; Semenza, 1999). Respiratory, circulatory, and 
hematopoietic systems are developed at the systemic level for oxygen uptake, transport, and 
delivery. Oxygen-sensing and responsive mechanisms are widely present in mammalian 
cells to maintain oxygen homeostasis by altering DNA replication, gene expression, and 
metabolism. In particular, the identification of HIF-1┙ (Wang & Semenza, 1993; Wang & 
Semenza, 1995) has immensely advanced the understanding of hypoxic response at the 
molecular level. 
HIF-1┙ is an oxygen-sensitive transcription factor that belongs to the PAS (Per–ARNT–Sim) 
superfamily (Wang et al, 1995) (Fig. 1). Upon dimerization with ARNT (arylhydrocarbon 
receptor nuclear translocator; also known as HIF-1┚), HIF-1┙ recognizes the hypoxia-
responsive element (5’-RCGTG-3’) in the promoter and/or enhancer of its target genes via a 
basic helix–loop–helix domain at the amino terminus (Semenza, 1999). HIF-1┙ 
heterodimerization depends on both the helix–loop–helix domain and the downstream PAS 
domain, which can be divided into two subdomains: PAS-A and PAS-B. Whereas PAS-A has 
been implicated in the heterodimerization and interaction with other proteins such as the heat 
shock protein 90 (Gradin et al, 1996; Semenza, 1999), the role of PAS-B remains less 
understood. HIF-1┙ harbors an oxygen-dependent degradation (ODD) domain that mediates 
proteolysis by the ubiquitin–proteasome pathway (Huang et al, 1998; Pugh et al, 1997). 
Hypoxia-stabilized HIF-1┙ recruits the transcription coactivator p300/CBP for transcriptional 
activation of its target genes via a potent transactivation domain at the carboxyl terminus 
(Arany et al, 1996; Gu et al, 2001; Kallio et al, 1998). Likewise, HIF-2┙ (also known as EPAS1) 
(Tian et al, 1997) shares similar structural domains with HIF-1┙ and binds to ARNT. 
HIF-1α is regulated primarily at the post-translational level (Huang & Bunn, 2003). Whereas 
both HIF-1┙ and ARNT are constitutively expressed at mRNA and protein levels, HIF-1α is 
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Fig. 1. Schematic representation of HIF-1α, ARNT, and HIF-2α. HIF-1α possesses a basic 
helix–loop–helix (bHLH) domain, a Per–ARNT–Sim (PAS) domain that can be divided into 
PAS-A and PAS-B, and a transactivation (TA) domain. Although similar domains can be 
found in ARNT based on sequence homology, an oxygen-dependent degradation (ODD) 
domain is uniquely present in HIF-1α. HIF-2α shares strong sequence homology with  
HIF-1α. 
extremely sensitive to proteolysis under oxygenated conditions (Gradin et al, 1996; Huang et 
al, 1996; Pugh et al, 1997). The ODD domain is crucial for HIF-1┙ proteolysis and is targeted 
for polyubiquitination by the E3 ubiquitin ligase containing the von Hippel-Lindau protein 
(pVHL) (Cockman et al, 2000; Ohh et al, 2000; Tanimoto et al, 2000). pVHL binding requires 
hydroxylation of two proline residues (Pro-402 and Pro-564 within the ODD domain) (Ivan 
et al, 2001; Jaakkola et al, 2001). Prolyl hydroxylation is catalyzed by a family of prolyl-4-
hydroxylases (EglN1, EglN2, and EglN3, which are widely known as PHD2, PHD1, and 
PHD3, respectively) that belong to the 2-oxoglutarate-dependent oxygenase superfamily 
(Bruick & McKnight, 2001; Epstein et al, 2001; Kaelin & Ratcliffe, 2008). Accordingly, these 
prolyl-4-hydroxylases sense and transduce oxygen signals through hydroxylation, resulting 
in polyubiquitination and degradation of HIF-1┙. By contrast, hypoxia inhibits the oxygen-
dependent enzymatic activity, thereby preventing HIF-1┙ degradation. Consequently, a 
stabilized HIF-1α exerts its transcriptional function through heterodimerization, DNA 
binding, and recruitment of p300/CBP for transactivation (Fig. 2).  
Given the widespread over-expression of HIF-1α and/or HIF-2α in solid cancers, this 
canonical mechanism of HIF-1α has been the guiding light for elucidating many of the 
pathological processes crucial for tumor growth and progression through the identification 
of numerous target genes of HIF-1α and HIF-2α (Bertout et al, 2008; Giaccia et al, 2003; 
Harris, 2002; Semenza, 2003). In particular, HIF-1α and HIF-2┙ have been shown to 
contribute to tumorigenesis, angiogenesis, metastasis, metabolism, and stem cell 
maintenance (Bertout et al, 2008; Majmundar et al, 2010). Despite these remarkable 
advancements in understanding the molecular basis of tumor hypoxia, the key question—
whether HIF-1α and HIF-2α are responsible for genetic alterations that drive malignant 
progression—remains unanswered. 
3. Regulation of DNA repair by hypoxia 
3.1 DNA repair and human cancer 
Hereditary defects in DNA repair have been linked with genetic instability and 
predispositions to cancer (Vogelstein & Kinzler, 2004). Genetic mutations in a host of  
DNA repair genes have been attributed to the development of a variety of human cancers 
including breast, colon, brain, and skin cancers, as well as leukemias and lymphomas.  
These genes participate in different pathways of DNA repair, such as mismatch 
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Fig. 2. The canonical mechanism of HIF-1┙ is responsible for the expression of various 
relevant genes and pathological processes in tumor development and progression. HRE, 
hypoxia-responsive element; EMT, epithelial–mesenchymal transition. 
repair (MSH2, MSH6), base excision repair (MUTYH), nucleotide excision repair (XPA), and 
double-strand break repair (NBS1, BRCA1). A wealth of knowledge has been gained that 
significantly advances our understanding of the biology of DNA repair and the mechanism of 
cancer development, and yet the role of DNA repair in the majority of cancers remains obscure 
because somatic mutations are rarely detected in DNA repair genes of sporadic cancers.  
3.2 Functional impairment of DNA repair by hypoxia 
To account for genetic alterations in sporadic cancers, functional impairment rather than 
genetic defect in DNA repair has been proposed on the basis of the evidence that hypoxia 
inhibits the expression of genes involved in DNA mismatch repair and double-strand break 
repair (Bindra & Glazer, 2005; Bristow & Hill, 2008; Huang et al, 2007). Indeed, multiple 
studies have shown hypoxic suppression of DNA repair genes including MLH1 (Mihaylova 
et al, 2003), MSH2 and MSH6 (Koshiji et al, 2005), RAD51 (Bindra et al, 2004), BRCA1 (Bindra 
et al, 2005), and NBS1 (To et al, 2006). Furthermore, it appears that hypoxia specifically 
inhibits homologous recombination but not non-homologous end joining, thereby 
inappropriately shunting double-strand break repair from high-fidelity homologous repair 
to error-prone non-homologous end joining. Moreover, hypoxic down-regulation of DNA 
repair genes results in DNA damage and genetic alteration, further supporting the notion 
that functional impairment of DNA repair induced by hypoxia contributes to genetic 
alterations in cancer. A challenging puzzle, however, is identifying the underlying 
mechanism by which hypoxia inhibits DNA repair. Some studies suggest that hypoxic 
down-regulation of RAD51 and BRCA1 involves formation of the E2F4/p130 repressive 
complex that occupies E2F sites in the target promoter (Bindra et al, 2005; Bindra & Glazer, 
2007). It remains unclear, however, how hypoxia signals the E2F4/p130 complex and 
whether this mechanism of genetic alteration is relevant in vivo to cancer biology.  
3.3 Mechanism of hypoxic inhibition of DNA repair 
In the process of understanding how hypoxia inhibits DNA repair, we made the following 
observations (Koshiji et al, 2005): i) HIF-1α but not HIF-2α was required for hypoxic 
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induction of microsatellite instability and down-regulation of MSH2 and MSH6 in MSH2-
proficient colon cancer cells; ii) ectopic expression of HIF-1α but not HIF-2α was sufficient to 
recapitulate the hypoxic effects; iii) whereas the transcriptional activator c-Myc was required 
for maintaining MSH2 and MSH6 expression, HIF-1α competed with c-Myc for occupying 
the target gene promoter via the DNA-binding factor Sp1; and iv) HIF-1α DNA-binding and 
transactivation domains were dispensable for MSH2 and MSH6 down-regulation. Hence, 
these findings have led us to propose a distinct mechanism by which HIF-1α inhibits DNA 
repair (Fig. 3), which is referred to hereafter as the HIF-1α–c-Myc pathway, in contrast to the 
aforementioned canonical mechanism as the HIF-1α–ARNT pathway.  
 
 
Fig. 3. A schematic representation of the HIF-1┙–c-Myc pathway, in which HIF-1┙ competes 
with c-Myc for Sp1 binding to the promoter of DNA repair genes, resulting in c-Myc 
displacement and therefore inhibition of DNA repair.  
In keeping with the finding that hypoxia inhibits DNA mismatch repair, we showed that the 
HIF-1┙–c-Myc pathway also accounted for hypoxic inhibition of NBS1 and induction of 
DNA double-strand break (To et al, 2006). We not only identified HIF-1┙ PAS-B as 
necessary and sufficient to mediate the HIF-1┙–c-Myc pathway, but also elucidated the 
molecular distinction between HIF-1┙ and HIF-2┙ that engenders functional difference in 
DNA repair. We demonstrated that despite strong sequence homology in the PAS-B 
subdomain, subtle differences between HIF-1┙ Val-317, Ala-321, and Thr-327 and the 
corresponding amino acid residues of HIF-2┙ essentially enabled HIF-1┙ to inhibit DNA 
repair (To et al, 2006). This important finding has prompted us to test the hypothesis that the 
HIF-1┙–c-Myc pathway is crucial to malignant progression. 
4. A mechanism of genetic alteration that drives malignant progression 
Although we provided a molecular mechanism by which HIF-1┙ but not HIF-2┙ mediates 
hypoxic induction of genetic alteration by inhibiting DNA repair, whether such mechanism 
is relevant to cancer biology had yet to be demonstrated. Given the close association of 
malignant progression with genetic alteration, we sought to test our hypothesis that the 
HIF-1┙–c-Myc pathway is crucial to malignant progression by inducing genetic alterations. 
To isolate the HIF-1┙–c-Myc pathway from the HIF-1┙–ARNT pathway, we elected to 
uncouple the two pathways by inactivating each individually with site-directed 
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mutagenesis. Mutations were carried out in the context of a stabilized form of HIF-1┙, 
designated as HIF1┙(PP) (Kageyama et al, 2004), in which the prolyl hydroxylation sites 
Pro-402 and Pro-564 had been destroyed to prevent oxygen-dependent proteolysis (Fig. 4). 
Subsequently, the HIF-1┙–c-Myc pathway was inactivated by substituting the 
aforementioned Val, Ala, Thr residues in the PAS-B domain with those of HIF-2┙, yielding 
the mutant HIF1┙(PP)+VAT (Yoo et al, 2011). Likewise, the HIF-1┙–ARNT pathway was 
disabled by mutating residues critical for DNA binding and transactivation (Gu et al, 2001; 
Koshiji et al, 2004; Land & Tee, 2007) to create the mutant HIF1┙(PP)+RFC. Our results 
showed that the two pathways are functionally independent because HIF1┙(PP)+VAT was 
functional only in the HIF-1┙–ARNT pathway, while HIF1┙(PP)+RFC was active only in the 
HIF-1┙–c-Myc pathway (Yoo et al, 2011). In contrast, HIF1┙(PP) was active in both 
pathways. 
 
 
 
 
 
 
Fig. 4. The HIF-1┙–ARNT pathway and the HIF-1┙–c-Myc pathway are functionally 
independent. Both pathways are inactivated individually by site-directed mutagenesis with 
substitutions of specific amino acid residues, as indicated, in the functional domains. 
After retroviral transduction with HIF1┙(PP) and HIF1┙(PP)+RFC, tumor cells exhibited 
conspicuous DNA double-strand breaks as indicated by a sharp increase of ┛-H2AX foci in 
the nucleus and microsatellite instability when analyzed with specific mononucleotide and 
dinucleotide markers (Yoo et al, 2011) (Fig. 5). Furthermore, there was a loss of the tumor 
suppressor genes FHIT and WWOX at the genomic level, indicative of chromosomal fragile 
site instability (Yoo et al, 2011). However, none of these DNA damage and genetic 
alterations were detected in cells expressing HIF1┙(PP)+VAT, which was functional only in 
the HIF-1┙–ARNT pathway.  
Importantly, all of these cells that had undergone genetic alterations not only acquired 
malignant traits including anchorage-independent growth and tumorigenicity but also 
became malignantly aggressive in mouse xenograft models, as indicated by rapid tumor 
growth, massive hemorrhagic necrosis, and rampant invasion of neighboring tissues (Yoo et 
al, 2011; Yoo et al, 2009). Moreover, advanced malignant progression was recapitulated in 
cells expressing HIF-1┙ PAS-B alone but not its VAT mutant. Altogether, these studies 
strongly indicate that the HIF-1┙–c-Myc pathway is the underlying mechanism of malignant 
progression by inhibiting DNA repair and inducing genetic alterations. 
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Fig. 5. The HIF-1┙–c-Myc pathway is responsible for DNA damage and genetic alteration. 
Left, Human osteosarcoma U-2 OS cells transduced with HIF-1┙ variants as specified were 
determined with immunofluorescence for colocalization (Merge) of the phosphorylated 
histone variant ┛-H2AX foci with those of 53BP1. Both serve as indicators of DNA damage, 
which were absent in the parental and HIF1┙(PP)+VAT cells. Right, The transduced cells 
were also analyzed for microsatellite instability, as indicated by the shortening (shift to the 
left) of genomic DNA fragments amplified with the mononucleotide marker BAT25. (Figure 
modified with permission from Yoo et al, 2011.) 
5. Conclusion 
Cancer remains one of the most deadly diseases overall and the leading cause of death in 
persons under the age of 85 years in the United States (Jemal et al, 2007). Technological 
advancements in cancer prevention and early detection have greatly reduced cancer 
incidence and mortality, yet the progressive nature of the disease seems to inevitably drive 
cancer to the advanced stage, posing an insurmountable challenge to the available 
treatments. The identification of the mechanism of hypoxia-driven malignant progression at 
the genetic level may provide a molecular basis for controlling the evolutionary process in 
tumors, a strategy proposed 35 years ago to combat tumor progression (Nowell, 1976). 
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